Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the safety of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Upsher-Smith Laboratories
• Treatments: Topiramate

Criteria

Inclusion Criteria:

• Have completed the maintenance period of the P09-004 study.

• Continue to be treated with a stable dose of 1 to a maximum of 3 approved concomitant AEDs.